Menu Search
Equities

Laboratorios Farmaceuticos ROVI SA

41L:DUS

Laboratorios Farmaceuticos ROVI SA

Actions
  • Price (EUR)77.05
  • Today's Change0.65 / 0.85%
  • Shares traded59.00
  • 1 Year change+63.10%
  • Beta--
Data delayed at least 15 minutes, as of Nov 06 2024 07:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.

  • Revenue in EUR (TTM)778.00m
  • Net income in EUR148.03m
  • Incorporated1946
  • Employees2.14k
  • Location
    Laboratorios Farmaceuticos ROVI SAC/ Julian Camarillo, 35MADRID 28037SpainESP
  • Phone+34 913756230
  • Fax+34 913047881
  • Websitehttps://www.rovi.es/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.